Biosimilar rituximab, marketed in Argentina as Novex, is subject to an active pharmacovigilance program that, according to Argentine law, must periodically report its status and results to regulatory authorities. In a recent study, researchers examined pharmacovigilance reports to compare the safety profile of biosimilar rituximab with that of its reference.
Biosimilar rituximab, marketed by Laboratorio Elea in Argentina as Novex, is subject to an active pharmacovigilance program that, according to Argentine law, must periodically report its status and results to regulatory authorities. In a study published in the June 7, 2017 issue of Hematological Oncology, researchers examined these pharmacovigilance reports in an effort to compare the safety profile of biosimilar rituximab with that of its reference.
A prospective treatment registry has been in place since the launch of the rituximab biosimilar. Prescribers are directed to report the age, gender, treatment start date, related pathology, dosing, and dose frequency for each patient receiving the biosimilar treatment. After a pre-determined period of time, physicians report treatment outcomes and occurrences of adverse events. For each adverse event, treating physicians file Individual Case Safety Reports (ICSRs).
Between November 26, 2014, to February 28, 2017, physicians registered a total of 584 patients who had been prescribed the biosimilar rituximab for non-Hodgkin’s Lymphoma. Among this group, 378 patients had at least 1 follow-up and were included in the analysis.
The median treatment duration was 214 days (interquartile range: 155 to 306). A mean of 5.7 cycles of rituximab were administered (range: 1 to 12). The total number of ICSRs filed was 15, and the occurrence rate was 1 ICSR filed per 100 cycles administered. Among adverse events reported on ICSRs, 10 were reported as being serious.
The adverse events reported are as follows (1 ICSR reported 2 events):
The researchers concluded that the biosimilar rituximab product demonstrated a safety profile similar to that of the reference product, and that the 2 products had comparable tolerability. The researchers further noted that the pharmacovigilance program showed great value in allowing for continuous monitoring of biosimilar product safety.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.